WallStSmart

Ero Copper Corp (ERO)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ero Copper Corp generates 1572% more annual revenue ($923.93M vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 31.6%. ERO trades at a lower P/E of 10.5x. ERO earns a higher WallStSmart Score of 78/100 (B+).

ERO

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 9.5Value: 5.7Quality: 6.5
Piotroski: 6/9Altman Z: 2.16

VMET

Buy

58

out of 100

Grade: C

Growth: 10.0Profit: 8.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EROSignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$26.93

Current Price

$30.45

$3.52 premium

UndervaluedFair: $26.93Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ERO6 strengths · Avg: 9.7/10
P/E RatioValuation
10.5x10/10

Attractively priced relative to earnings

Return on EquityProfitability
32.5%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
31.6%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
34.7%10/10

Strong operational efficiency at 34.7%

Revenue GrowthGrowth
110.4%10/10

Revenue surging 110.4% year-over-year

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

VMET5 strengths · Avg: 9.8/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

ERO0 concerns · Avg: 0/10

No major concerns identified

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.26B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ERO

The strongest argument for ERO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 31.6% and operating margin at 34.7%. Revenue growth of 110.4% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : ERO

No major red flags identified for ERO, but monitor valuation.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

ERO generates stronger free cash flow (20M), providing more financial flexibility.

Monitor COPPER industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ERO scores higher overall (78/100 vs 58/100), backed by strong 31.6% margins and 110.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ero Copper Corp

BASIC MATERIALS · COPPER · USA

Ero Copper Corp. The company is headquartered in Vancouver, Canada.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.

Want to dig deeper into these stocks?